The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility
- 105 Downloads
The Japanese Society of Chemotherapy (JSC) conducted the first nationwide surveillance of bacterial respiratory pathogens during the period from January to August 2006. With the cooperation of 32 medical institutions throughout Japan, a total of 924 strains belonging to seven clinically relevant bacterial species were collected from adult patients with well-diagnosed respiratory tract infections (RTIs). Antimicrobial susceptibility testing of the 887 evaluable strains (205 Staphylococcus aureus, 200 Streptococcus pneumoniae, 9 Streptococcus pyogenes, 165 Haemophilus influenzae, 91 Moraxella catarrhalis, 74 Klebsiella pneumoniae, and 143 Pseudomonas aeruginosa) to 42 antibacterial agents was conducted at the Central Laboratory of the Research Center for Anti-infective Drugs of the Kitasato Institute, according to recommendations issued by the Clinical and Laboratory Standards Institute (CLSI). The antibacterial agents employed were 25 β-lactams, three aminoglycosides, four macrolides (including one azalide and one ketolide), one lincosamide, one tetracycline, two glycopeptides, five fluoroquinolones, and one oxazolidinone. The incidence of methicillin-resistant S. aureus (MRSA) was 63.4%, and the incidences of penicillin-intermediately resistant S. pneumoniae (PISP) and penicillin-resistant S. pneumoniae (PRSP) were 35.0% and 4.0%, respectively. Among H. influenzae, 21.2% of the strains were found to be β-lactamase-nonproducing ampicillin (ABPC)-intermediately resistant (BLNAI), 29.1% to be β-lactamase-nonproducing ABPC-resistant (BLNAR), and 4.8% to be β-lactamaseproducing ABPC-resistant (BLPAR) strains. The incidence of extended-spectrum β-lactamase-producing K. pneumoniae was 2.7% (2 of 74 strains). Three (2.1%) of the 143 P. aeruginosa strains were found to be metallo-β-lactamaseproducing, including 1 (0.7%) multidrug-resistant strain. Through the nationwide surveillance, we obtained fundamental antimicrobial susceptibility data of clinically relevant bacterial pathogens in adult RTI to various antibacterial agents. These data will be a useful reference for future periodic surveillance studies, as well as for investigations to control antimicrobial-resistant pathogens.
Key wordsSurveillance Susceptibility Drug Resistance Respiratory tract infection
Unable to display preview. Download preview PDF.
- 1.The Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults 2000 (in Japanese). Tokyo: The Japanese Respiratory Society; 2000.Google Scholar
- 2.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 16th informational supplement M100-S16 and M45-P. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. Document M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.Google Scholar
- 10.Kamiya H, Kato T, Togashi T, Iwata S, Kurosaki T, Baba S, et al. The Research Group on Streptococcus pneumoniae Serotypes among Children. Epidemiological survey of Pneumococcus serotypes in pediatric patients with acute suppurative otitis media (in Japanese; abstract in English). Kansenshogaku Zasshi 2007;81:59–66.PubMedGoogle Scholar
- 11.Chiba N, Kobayashi R, Hasegawa K, Morozumi M, Nakayama E, Tajima T, et al. Acute Respiratory Diseases Study Group. Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of Streptococcus pneumoniae isolates from community-acquired pneumonia in children. J Antimicrob Chemother 2005;56:756–760.PubMedCrossRefGoogle Scholar
- 12.James A, Karlowsky JA, Thornsberry C, Critchley IA, Jones ME, Evangelista AT, et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000–2001 and 2001–2002 TRUST Studies in the United States. Antimicrob Agents Chemother 2003;47:1790–1797.CrossRefGoogle Scholar
- 13.Hasegawa K, Kobayashi R, Takada E, Ono A, Chiba N, Morozumi M, et al. Nationwide Surveillance for Bacterial Meningitis. High prevalence of type b beta-lactamase-non-producing ampicillinresistant Haemophilus influenzae in meningitis: the situation in Japan where Hib vaccine has not been introduced. J Antimicrob Chemother 2006;57:1077–1082.PubMedCrossRefGoogle Scholar